New Treatment Enhances Cardiac Care Options
SYDNEY — Phebra, an Australian pharmaceutical company, has introduced Rapiblyk, a medication designed to manage severe cardiac arrhythmias, to healthcare settings across Australia. The announcement, made on 10 March 2026, marks a significant addition to Phebra’s critical care offerings. This new treatment option is expected to fill an important gap in the management of cardiac conditions, providing an alternative for patients who require precise heart rate control.
The newly launched Rapiblyk, which contains landiolol hydrochloride, is noted for its ultra-short-acting properties that allow for precise control of heart rates in critical situations, according to Phebra CEO Andre Vlok. Vlok emphasised the medication’s established track record in Japan, Europe, and the United States, stating it provides “unmatched reliability and safety for patients experiencing life-threatening cardiac events.” The introduction of Rapiblyk is part of Phebra’s ongoing commitment to advancing healthcare solutions and improving patient outcomes in Australia.
Source: newshub.medianet.com.au
Last updated: 2 April 2026, 4:34 pm
